Early Alzheimer’s Damage Emerges Outside the Hippocampus

Alzheimer’s disease may leave measurable scars in the brain long before memory loss becomes obvious. In a Johns Hopkins analysis of hundreds of MRI and PET scans, the earliest structural changes appeared in the entorhinal cortex and amygdala, two regions tied to memory and emotion, rather than in the hippocampus, which has long been the standard imaging focus for Alzheimer’s-related injury.

The finding matters because it reframes where clinicians may need to look when searching for the first anatomical signs of the disease. The hippocampus still plays a central role in memory, but this work suggests it may not be the first structure to show the earliest measurable atrophy. In practical terms, a scan that concentrates too narrowly on the hippocampus could miss a window of disease activity that is already underway.

“This work demonstrates that the entorhinal cortex, in blue, and the amygdala, in red, predict early Alzheimer’s disease better than the hippocampus, shown in green,” the investigators wrote in their summary of the imaging findings.

A Decade-Long Biological Runway Before Symptoms

Alzheimer’s does not begin when a person starts repeating questions or misplacing keys. The pathology accumulates over years, often decades, before family members or clinicians notice a clear cognitive shift. Michael Miller, the senior author, described that preclinical interval as a long runway of brain change, saying the disease can show “clinical biomarkers of atrophy as much as a decade before there are clinical symptoms.”

He also pointed to the therapeutic implications of that timing. If the brain is already changing five to 10 years before memory loss appears, then treatment aimed at the earliest stage could arrive while enough neural reserve remains to matter. The biological logic is straightforward: once widespread neuronal loss has taken hold, preserving function becomes far harder than interrupting the process while tissue is still salvageable.

Alzheimer’s disease is the most common cause of dementia worldwide, but its silent phase is what creates the biggest diagnostic problem. By the time memory impairment is visible, injury has already advanced. Biomarkers are designed to narrow that gap by exposing disease biology before symptoms become irreversible.

The Johns Hopkins team examined scans from two independent research efforts: the Alzheimer’s Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study. Those cohorts included people without symptoms, individuals with cognitive impairment, and patients who later died from the disease, allowing the investigators to compare brain structure across the Alzheimer’s spectrum.

Across both datasets, the same pattern emerged. The entorhinal cortex and amygdala showed greater relative tissue loss early in the disease course than the hippocampus. The entorhinal cortex helps retrieve previously stored memories, while the amygdala contributes to emotional memory and the processing of emotionally charged experiences. Their vulnerability fits with the way Alzheimer’s can quietly distort both memory formation and emotional salience before more obvious disorientation arrives.

A single sentence captures the clinical significance: the first visible atrophy may not be where neurologists have traditionally been looking.

That shift could influence how imaging is interpreted in high-risk patients. Family history, age, or other risk factors may justify closer scrutiny of these regions, especially if future scanners and analytic tools can reliably quantify subtle volume loss before cognition declines.

Tau, Gray Matter, and the Structural Signature of Disease

The imaging findings were paired with a molecular clue: abnormal tau protein accumulation. Under healthy conditions, tau helps support the internal structure of nerve cells. In Alzheimer’s, tau becomes misfolded and aggregates into tangles that disrupt neuronal function and eventually contribute to cell death.

Using PET imaging and digital pathology, the researchers found overlap between gray matter shrinkage and regions showing tau-related change. Gray matter contains many of the brain’s neuron cell bodies and is central to information processing. When atrophy appears in gray matter-rich areas alongside tau pathology, the anatomical change becomes more than a vague sign of aging; it becomes a structural reflection of a specific disease mechanism.

The overlap strengthens the case for viewing the entorhinal cortex and amygdala as early biomarkers rather than incidental findings. It also supports a mechanistic explanation for why these regions may fail early: once tau begins accumulating in vulnerable circuits, tissue loss follows in the same neighborhood.

Earlier Risk Stratification Could Change Clinical Practice

Marilyn Albert, a co-author and director of the Johns Hopkins Alzheimer’s Disease Research Center, said the goal is to identify people before symptoms emerge so treatment can begin early enough to slow or stop progression. Meaghan Morris, a neuropathologist and co-author, said this could improve risk stratification for identifying who is likely to develop cognitive decline in the near future.

The concept is clinically important because it shifts Alzheimer’s management toward prevention rather than reaction. If biomarkers can identify who is on a trajectory toward decline, clinicians could prioritize follow-up, counseling, and future therapies for the people most likely to benefit. As imaging becomes more accessible and less expensive, the researchers envision a future in which these measures might even be informative in a person’s 30s or 40s when family risk is high.

The prospect is compelling, but the current evidence still stops short of a diagnostic tool. These scans identify candidate biomarkers, not a validated test that can tell an individual patient exactly when Alzheimer’s will begin.

What Still Needs to Be Proved

The study offers a strong anatomical signal, but clinical use will require more work. The next step is to examine what happens at a smaller scale inside these regions, especially the molecular changes surrounding abnormal tau accumulation and the local tissue environment that accompanies it. Miller said future work will focus on the “molecular neighborhoods” linked to the atrophy patterns seen on imaging.

That direction makes sense biologically. Structural decline is the visible endpoint of a deeper process, and therapies are more likely to succeed if they target the molecular cascade before neuronal networks collapse. Understanding those local changes could reveal new intervention points and help explain why these two regions deteriorate earlier than the hippocampus in the first place.

For now, the study reframes early Alzheimer’s detection around a broader and earlier anatomical footprint. The hippocampus remains important, but the first detectable warning signs may lie beside it, not within it. Clinical application will depend on whether these imaging markers prove reliable across larger populations and whether they can predict future cognitive decline with enough precision to guide care.


Reporting by Dr. A. Manasa, MBBS for Medicine World Foundation, with additional data provided by ScienceDaily Health & Medicine.